and the company has a highly promising pipeline of additional cannabinoid drug candidates in development.discover more about gw ... meeting patients needssativex is approved to treat spasticity muscle stiffness and spasm due to multiple sclerosis offering relief to patients for a condition that previously had limited treatment options.patient information can be found here ... world leading sciencegw is recognised as a world leader in cannabinoid science and works closely with a global network of clinicians and scientific collaborators at 25 academic institutions across the world.more about our scientific collaborations ... a valuable pipelinegw is also researching medicines based upon its validated cannabinoid platform to treat a range of other conditions including pain cancer diabetes and epilepsy.our areas of therapeutic interest ... an exciting futurewith a commercial product valuable pipeline prestigious pharmaceutical partners diversified business model and a highly capable in house team gw is well placed for growth and value creation.learn more about our future opportunities ... sativexinformation for patients and medical professionals can be found here ... gw researchtherapeutic areas of focus clinical trials and information on epidiolex media centrepress releases faqs & contact information for media enquiries ... investorsshare price regulatory news company presentations and other investor information latest newsgw pharmaceuticals announces second positive phase 3 pivotal trial for epidiolex ... 26 september 2016gw pharmaceuticals to present at the morgan stanley global healthcare conference ... 7 september 2016view all newsepidiolexthe fda has granted orphan designation for epidiolex epidiolex is an investigational drug and has not been approved for use by the fda or any other national regulatory agencyview press releasemore information on epidiolexshare price nasdaq gwph126 .39 2.14 2016 10 14 16 00 00share price aim gwpshare priceshare chart gw pharmaceuticals 2014homesitemapaccessibility disclosure & disclaimercontactprivacy